Cytokinetics Additional Data on Aficamten for hypertrophic cardiomyopathy

 

Treatment with Aficamten for 48 Weeks is Associated with Improvements in Clinical Efficacy Endpoints, NYHA Class and Cardiac Biomarkers, Structure and Function

https://www.globenewswire.com/news-release/2024/04/05/2858458/35409/en/Cytokinetics-Presents-Additional-48-Week-Data-From-FOREST-HCM-the-Open-Label-Extension-Clinical-Study-of-Aficamten-at-The-American-College-of-Cardiology-73%CA%B3%E1%B5%88-Annual-Scientific-Sess.html